X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs MERCK LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA MERCK LTD DISHMAN PHARMA/
MERCK LTD
 
P/E (TTM) x 25.1 33.8 74.2% View Chart
P/BV x 3.3 3.8 88.4% View Chart
Dividend Yield % 0.7 0.7 88.9%  

Financials

 DISHMAN PHARMA   MERCK LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
MERCK LTD
Dec-16
DISHMAN PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs3741,060 35.3%   
Low Rs129623 20.7%   
Sales per share (Unadj.) Rs197.8632.4 31.3%  
Earnings per share (Unadj.) Rs21.245.7 46.4%  
Cash flow per share (Unadj.) Rs34.762.3 55.7%  
Dividends per share (Unadj.) Rs2.0011.00 18.2%  
Dividend yield (eoy) %0.81.3 60.8%  
Book value per share (Unadj.) Rs179.9388.8 46.3%  
Shares outstanding (eoy) m80.6916.60 486.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.3 95.6%   
Avg P/E ratio x11.918.4 64.5%  
P/CF ratio (eoy) x7.213.5 53.7%  
Price / Book Value ratio x1.42.2 64.6%  
Dividend payout %9.424.1 39.2%   
Avg Mkt Cap Rs m20,30613,969 145.4%   
No. of employees `0000.81.6 52.4%   
Total wages/salary Rs m5,3551,487 360.2%   
Avg. sales/employee Rs Th19,252.76,631.9 290.3%   
Avg. wages/employee Rs Th6,459.5939.2 687.8%   
Avg. net profit/employee Rs Th2,064.1479.4 430.5%   
INCOME DATA
Net Sales Rs m15,96110,498 152.0%  
Other income Rs m265242 109.5%   
Total revenues Rs m16,22610,741 151.1%   
Gross profit Rs m4,1031,135 361.4%  
Depreciation Rs m1,091276 395.9%   
Interest Rs m9440-   
Profit before tax Rs m2,3341,102 211.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624343 181.6%   
Profit after tax Rs m1,711759 225.5%  
Gross profit margin %25.710.8 237.7%  
Effective tax rate %26.731.1 85.8%   
Net profit margin %10.77.2 148.3%  
BALANCE SHEET DATA
Current assets Rs m11,0186,410 171.9%   
Current liabilities Rs m9,5178,828 107.8%   
Net working cap to sales %9.4-23.0 -40.8%  
Current ratio x1.20.7 159.5%  
Inventory Days Days11058 191.6%  
Debtors Days Days3538 90.8%  
Net fixed assets Rs m16,3041,406 1,159.3%   
Share capital Rs m161166 97.2%   
"Free" reserves Rs m12,9076,286 205.3%   
Net worth Rs m14,5166,455 224.9%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8058,828 337.6%  
Interest coverage x3.5NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.2 45.0%   
Return on assets %8.98.6 103.6%  
Return on equity %11.811.8 100.3%  
Return on capital %17.517.1 102.7%  
Exports to sales %24.88.3 299.3%   
Imports to sales %3.721.0 17.8%   
Exports (fob) Rs m3,956869 455.0%   
Imports (cif) Rs m5962,209 27.0%   
Fx inflow Rs m4,952959 516.4%   
Fx outflow Rs m6972,612 26.7%   
Net fx Rs m4,255-1,653 -257.4%   
CASH FLOW
From Operations Rs m2,7861,070 260.3%  
From Investments Rs m-1,529-750 203.9%  
From Financial Activity Rs m-941-150 628.2%  
Net Cashflow Rs m316171 185.1%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 3.7 18.2 20.3%  
FIIs % 12.7 1.0 1,270.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 29.1 75.9%  
Shareholders   46,261 28,591 161.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  J.B.CHEMICALS  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; ONGC Rallies 6.3%(09:30 am)

Asian stock markets traded on a mixed note in morning trade as market participants kept an eye on political developments in the U.S. after a government shutdown began last week.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS